CytomX Historical Cash Flow

CTMX Stock

USD 1.21 0.05 3.97%

Analysis of CytomX Therapeutics cash flow over time is an excellent tool to project CytomX Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 11.2 M or Begin Period Cash Flow of 146.2 M as it is a great indicator of CytomX Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining CytomX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytomX Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

About CytomX Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in CytomX balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which CytomX's non-liquid assets can be easily converted into cash.

CytomX Therapeutics Cash Flow Chart

At this time, CytomX Therapeutics' Change To Inventory is fairly stable compared to the past year. Stock Based Compensation is likely to rise to about 11.2 M in 2024, despite the fact that Change In Cash is likely to grow to (167.7 M).

Stock Based Compensation Begin Period Cash Flow Capital Expenditures End Period Cash Flow

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by CytomX Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of CytomX Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most accounts from CytomX Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Change To Inventory is fairly stable compared to the past year. Stock Based Compensation is likely to rise to about 11.2 M in 2024, despite the fact that Change In Cash is likely to grow to (167.7 M).

CytomX Therapeutics cash flow statement Correlations

	Change To Inventory	Change In Cash	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Change To Account Receivables	Net Income	End Period Cash Flow	Change To Liabilities	Sale Purchase Of Stock	Investments	Net Borrowings	Change To Operating Activities	Change To Netincome	Change Receivables	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Issuance Of Capital Stock
Change To Inventory		-0.13	0.17	-0.08	-0.08	0.21	0.16	-0.14	-0.07	0.25	-0.05	0.14	0.16	0.83	0.01	0.28	0.42	0.27	0.36	0.43	-0.17	0.02
Change In Cash	-0.13		-0.07	0.4	0.66	-0.33	-0.26	0.59	0.36	-0.65	-0.4	0.43	0.37	-0.41	-0.04	-0.16	0.67	-0.14	-0.03	0.52	0.31	0.71
Stock Based Compensation	0.17	-0.07		-0.41	-0.2	0.92	0.92	0.18	0.76	0.01	-0.7	0.84	0.13	0.52	0.86	0.75	-0.05	0.92	0.38	-0.49	-0.46	-0.58
Free Cash Flow	-0.08	0.4	-0.41		0.92	-0.57	-0.49	0.5	-0.33	-0.06	0.49	-0.23	0.75	-0.46	-0.64	-0.19	0.25	-0.14	-0.64	0.65	0.83	0.49
Change In Working Capital	-0.08	0.66	-0.2	0.92		-0.44	-0.35	0.71	-0.03	-0.34	0.11	0.09	0.84	-0.46	-0.41	-0.09	0.4	0.01	-0.56	0.61	0.7	0.54
Begin Period Cash Flow	0.21	-0.33	0.92	-0.57	-0.44		0.95	0.03	0.57	0.08	-0.59	0.7	-0.06	0.64	0.78	0.69	-0.24	0.85	0.37	-0.64	-0.57	-0.77
Depreciation	0.16	-0.26	0.92	-0.49	-0.35	0.95		0.13	0.53	0.04	-0.59	0.72	0.01	0.58	0.83	0.73	-0.24	0.85	0.25	-0.61	-0.51	-0.73
Other Non Cash Items	-0.14	0.59	0.18	0.5	0.71	0.03	0.13		0.14	-0.65	-0.37	0.47	0.77	-0.32	0.0	0.04	0.25	0.31	-0.59	0.16	0.26	0.22
Capital Expenditures	-0.07	0.36	0.76	-0.33	-0.03	0.57	0.53	0.14		-0.17	-0.78	0.82	0.01	0.14	0.72	0.38	0.22	0.6	0.55	-0.28	-0.33	-0.15
Change To Account Receivables	0.25	-0.65	0.01	-0.06	-0.34	0.08	0.04	-0.65	-0.17		0.55	-0.39	-0.18	0.35	-0.12	0.1	-0.06	0.12	0.24	-0.05	-0.11	-0.2
Net Income	-0.05	-0.4	-0.7	0.49	0.11	-0.59	-0.59	-0.37	-0.78	0.55		-0.86	-0.03	-0.2	-0.79	-0.39	-0.2	-0.52	-0.35	0.34	0.57	0.15
End Period Cash Flow	0.14	0.43	0.84	-0.23	0.09	0.7	0.72	0.47	0.82	-0.39	-0.86		0.23	0.33	0.71	0.56	0.28	0.72	0.34	-0.21	-0.31	-0.2
Change To Liabilities	0.16	0.37	0.13	0.75	0.84	-0.06	0.01	0.77	0.01	-0.18	-0.03	0.23		-0.15	-0.15	0.24	0.33	0.42	-0.58	0.39	0.39	0.25
Sale Purchase Of Stock	0.83	-0.41	0.52	-0.46	-0.46	0.64	0.58	-0.32	0.14	0.35	-0.2	0.33	-0.15		0.38	0.54	0.07	0.5	0.56	-0.06	-0.43	-0.46
Investments	0.01	-0.04	0.86	-0.64	-0.41	0.78	0.83	0.0	0.72	-0.12	-0.79	0.71	-0.15	0.38		0.69	-0.15	0.66	0.44	-0.6	-0.62	-0.51
Net Borrowings	0.28	-0.16	0.75	-0.19	-0.09	0.69	0.73	0.04	0.38	0.1	-0.39	0.56	0.24	0.54	0.69		-0.12	0.72	0.2	-0.33	-0.31	-0.54
Change To Operating Activities	0.42	0.67	-0.05	0.25	0.4	-0.24	-0.24	0.25	0.22	-0.06	-0.2	0.28	0.33	0.07	-0.15	-0.12		-0.03	0.25	0.68	0.03	0.77
Change To Netincome	0.27	-0.14	0.92	-0.14	0.01	0.85	0.85	0.31	0.6	0.12	-0.52	0.72	0.42	0.5	0.66	0.72	-0.03		0.13	-0.36	-0.31	-0.54
Change Receivables	0.36	-0.03	0.38	-0.64	-0.56	0.37	0.25	-0.59	0.55	0.24	-0.35	0.34	-0.58	0.56	0.44	0.2	0.25	0.13		-0.05	-0.4	-0.11
Cash And Cash Equivalents Changes	0.43	0.52	-0.49	0.65	0.61	-0.64	-0.61	0.16	-0.28	-0.05	0.34	-0.21	0.39	-0.06	-0.6	-0.33	0.68	-0.36	-0.05		0.63	0.77
Cash Flows Other Operating	-0.17	0.31	-0.46	0.83	0.7	-0.57	-0.51	0.26	-0.33	-0.11	0.57	-0.31	0.39	-0.43	-0.62	-0.31	0.03	-0.31	-0.4	0.63		0.35
Issuance Of Capital Stock	0.02	0.71	-0.58	0.49	0.54	-0.77	-0.73	0.22	-0.15	-0.2	0.15	-0.2	0.25	-0.46	-0.51	-0.54	0.77	-0.54	-0.11	0.77	0.35

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change To Inventory	19.9M	(11.3M)	(11.1M)	11.6M	13.4M	14.1M
Change In Cash	(59.2M)	3.4M	13.7M	(11.9M)	(176.5M)	(167.7M)
Stock Based Compensation	19.1M	14.8M	13.2M	13.1M	8.6M	11.2M
Free Cash Flow	(144.0M)	3.0M	(120.6M)	(112.5M)	(56.9M)	(54.0M)
Change In Working Capital	(59.3M)	18.1M	(54.7M)	(30.7M)	(62.5M)	(59.4M)
Begin Period Cash Flow	248.5M	189.3M	192.8M	206.4M	194.6M	146.2M
Other Cashflows From Financing Activities	25K	5.6M	2.5M	648K	30.2M	17.1M
Depreciation	2.6M	2.6M	2.7M	2.4M	2.2M	2.0M
Other Non Cash Items	1.6M	2.9M	3.1M	3.6M	(3.7M)	(3.5M)
Capital Expenditures	3.5M	2.3M	1.6M	1.7M	840K	798K
Total Cash From Operating Activities	(140.5M)	5.3M	(119.0M)	(110.8M)	(56.0M)	(53.2M)
Change To Account Receivables	84K	(785K)	8K	(35.2M)	32.6M	34.2M
Net Income	(102.2M)	(32.9M)	(83.6M)	(99.3M)	(569K)	(597.5K)
Total Cash From Financing Activities	1.6M	16.9M	110.2M	648K	30.2M	36.8M
End Period Cash Flow	189.3M	192.8M	206.4M	194.6M	18.1M	17.2M
Change To Liabilities	261K	(374K)	(857K)	(139K)	(125.1K)	(118.8K)
Sale Purchase Of Stock	139.6M	1.6M	16.9M	110.2M	126.7M	133.1M
Investments	9.7M	83.2M	(16.4M)	24.1M	(63.7M)	(60.5M)
Total Cashflows From Investing Activities	5.9M	79.7M	(18.7M)	22.5M	25.9M	27.2M
Change To Operating Activities	(11.3M)	(11.1M)	11.6M	(12.1M)	(10.9M)	(10.3M)
Change To Netincome	16.9M	20.7M	14.8M	13.2M	15.1M	14.7M
Change Receivables	10.0M	84K	(785K)	8K	9.2K	9.7K
Cash And Cash Equivalents Changes	70.0M	(59.2M)	3.4M	13.7M	12.3M	18.2M
Cash Flows Other Operating	(59.0M)	22.7M	(57.7M)	(19.2M)	(17.3M)	(18.1M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Historical Cash Flow

About CytomX Cash Flow Analysis

CytomX Therapeutics Cash Flow Chart

Stock Based Compensation

Begin Period Cash Flow

Capital Expenditures

CytomX Therapeutics cash flow statement Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics cash flow statement Accounts

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation	+ 0.95	Begin Period Cash Flow
Begin Period Cash Flow	+ 0.92	Stock Based Compensation
Depreciation	+ 0.92	Stock Based Compensation
Change To Netincome	+ 0.92	Stock Based Compensation
Change In Working Capital	+ 0.92	Free Cash Flow
Investments	+ 0.86	Stock Based Compensation

End Period Cash Flow	- 0.86	Net Income
Investments	- 0.79	Net Income
Net Income	- 0.78	Capital Expenditures
Issuance Of Capital Stock	- 0.77	Begin Period Cash Flow
Issuance Of Capital Stock	- 0.73	Depreciation
Net Income	- 0.7	Stock Based Compensation